OBiS releases preliminary results from its 2014 global physician breast cancer survey. The survey included treatment data and insights from over 50 countries and 500 treating physicians.
Data demonstrated that despite a number of newly approved targeted therapies, most physicians treated their patients with more traditional standard of care chemotherapy options. Physicians answered that they only anticipate an increase in usage of the targeted agents Ado-Trastuzumab Emtansine and Pertuzumab. From our physician sample the majority of patients included in the analysis were adjuvant.
The survey is now closed and complete results and geographic analyses are available upon request.
New discovery could lead to improved treatments for age- and cancer-related muscle degeneration